Literature DB >> 12631133

Renal survival and prognostic factors in patients with PR3-ANCA associated vasculitis with renal involvement.

Marjan C Slot1, Jan Willem Cohen Tervaert, Casper F M Franssen, Coen A Stegeman.   

Abstract

BACKGROUND: Severe renal disease is a feature of anti-neutrophil cytoplasmic antibodies (ANCA)-associated small-vessel vasculitis. We evaluated patient and renal survival and prognostic factors in patients with PR3-ANCA associated vasculitis with renal involvement at diagnosis during long-term follow-up.
METHODS: Eighty-five patients were diagnosed between 1982 and 1996 and followed until 2001 allowing >or=5 years of follow-up. All patients were treated with prednisolone and cyclophosphamide. Univariate and multivariate analyses with patient and renal survival as dependent variables were performed.
RESULTS: Of the 85 patients in this study, 17 (20%) died within one year after diagnosis. Of the 25 patients (29%) who were dialysis dependent at diagnosis, two remained dependent and two again became dialysis dependent after less than one year; nine died early without renal recovery. Risk factors for death occurring within one year in univariate analysis (RR, 95% CI) were age>65 years (6.5, 1.6-13.7) and dialysis dependency at diagnosis (3.6, 1.0-13). Twenty patients died beyond one year during the long-term follow-up. Male gender (4.7, 1.6-10) and developing dialysis dependency during follow-up (4.1, 1.4-12) were associated with poor outcome. Risk factor for renal failure within one year was dialysis dependency at diagnosis (29, 3.6-229). Of 64 patients dialysis independent one year after diagnosis, 12 patients became dialysis dependent during follow-up. A renal relapse was strongly associated with development of renal failure in long-term follow-up (17, 3.5-81).
CONCLUSIONS: Early death and failure to recover renal function in PR3-ANCA associated vasculitis is associated with age> 65 years and dialysis dependency at diagnosis. Long-term renal survival is determined by renal relapses during follow-up only. Slow, progressive renal failure without relapses is rarely observed in this group.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12631133     DOI: 10.1046/j.1523-1755.2003.00769.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  40 in total

1.  Systemic necrotizing vasculitides in Turkey: a comparative analysis of 40 consecutive patients.

Authors:  Sevil Kamali; Murat Inanc; Ahmet Gul; Lale Ocal; Nuray Gurel Polat; Isin Kilicaslan; Orhan Aral; Meral Konice
Journal:  Rheumatol Int       Date:  2004-09-15       Impact factor: 2.631

Review 2.  Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta-analysis.

Authors:  Michael Walsh; Fausta Catapano; Wladimir Szpirt; Kristian Thorlund; Annette Bruchfeld; Loic Guillevin; Marion Haubitz; Peter A Merkel; Chen Au Peh; Charles Pusey; David Jayne
Journal:  Am J Kidney Dis       Date:  2010-12-30       Impact factor: 8.860

3.  Clinical characteristics and outcome of pauci-immune glomerulonephritis in African Americans.

Authors:  Duvuru Geetha; Caroline J Poulton; Yichun Hu; Philip Seo; Julie Anne G McGregor; Ronald J Falk; Susan L Hogan
Journal:  Semin Arthritis Rheum       Date:  2013-12-04       Impact factor: 5.532

Review 4.  Anti-neutrophil Cytoplasmic Antibodies (ANCA) as Disease Activity Biomarkers in a "Personalized Medicine Approach" in ANCA-Associated Vasculitis.

Authors:  Mohammed S Osman; Jan Willem Cohen Tervaert
Journal:  Curr Rheumatol Rep       Date:  2019-12-26       Impact factor: 4.592

5.  Outcome and treatment of elderly patients with ANCA-associated vasculitis.

Authors:  Maria Weiner; Su Mein Goh; Aladdin J Mohammad; Zdenka Hruskova; Anisha Tanna; Annette Bruchfeld; Daina Selga; Zdenka Chocova; Kerstin Westman; Per Eriksson; Charles D Pusey; Vladimir Tesar; Alan D Salama; Mårten Segelmark
Journal:  Clin J Am Soc Nephrol       Date:  2015-06-22       Impact factor: 8.237

6.  Determinants of renal and patient outcomes in a Spanish cohort of patients with ANCA-associated vasculitis and renal involvement.

Authors:  H Marco; J Draibe; J Villacorta; L F Quintana; N Martin; R Garcia-Osuna; C Cabre; M A Martín-Gómez; A Balius; A Saurina; M Picazo; I Gich-Saladich; M Navarro-Díaz; M Praga; T Cavero; J Ballarin; M M Díaz-Encarnación
Journal:  Clin Rheumatol       Date:  2018-03-09       Impact factor: 2.980

Review 7.  ANCA-associated vasculitis with renal involvement.

Authors:  Valentina Binda; Gabriella Moroni; Piergiorgio Messa
Journal:  J Nephrol       Date:  2017-05-30       Impact factor: 3.902

8.  Mycophenolate mofetil for induction and maintenance of remission in microscopic polyangiitis with mild to moderate renal involvement--a prospective, open-label pilot trial.

Authors:  Francisco Silva; Ulrich Specks; Sanjay Kalra; Marie C Hogan; Nelson Leung; Sanjeev Sethi; Fernando C Fervenza
Journal:  Clin J Am Soc Nephrol       Date:  2010-01-21       Impact factor: 8.237

9.  ANCA-Positive Patients: The Influence of PR3 and MPO Antibodies on Survival Rate and The Association with Clinical and Laboratory Characteristics.

Authors:  J C Drooger; A Dees; A J G Swaak
Journal:  Open Rheumatol J       Date:  2009-03-04

10.  Monocyte chemoattractant protein 1 is a prognostic marker in ANCA-associated small vessel vasculitis.

Authors:  Sophie Ohlsson; Omran Bakoush; Jan Tencer; Ole Torffvit; Mårten Segelmark
Journal:  Mediators Inflamm       Date:  2009-07-05       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.